Connect with us

Health

INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa – Yahoo Finance

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious…

Published

on

Article feature image

Phase 1B clinical trial is first study for Lassa fever conducted in Africa
Goal is for vaccine to be available for emergency use as stockpile product following Phase 2
Progress on INO-4500 reflects INOVIO’s focus on and continued commitment to the fight against infectious diseases
Trial fully funded by the Coalition for Epidemic Preparedness (CEPI)
PLYMOUTH MEETING, Pa., Feb. 23, 2021 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed…

Click here to view the original article.